Tirzepatide has two brand names: Mounjaro and Zepbound, both made by Eli Lilly. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. The drug inside is the same molecule at the same six strengths. There is no FDA-approved generic tirzepatide, and compounded tirzepatide is not a generic. If you are new to the drug, start with our tirzepatide guide.
Key takeaways
- Mounjaro (tirzepatide) was approved on May 13, 2022 under NDA 215866 to improve blood sugar control in adults with type 2 diabetes.
- Zepbound (tirzepatide) was approved on November 8, 2023 under NDA 217806 for chronic weight management, and on December 20, 2024 for moderate to severe obstructive sleep apnea in adults with obesity.
- Both come in the same six strengths, 2.5 mg to 15 mg, on the same once-weekly schedule.
- The generic name for Mounjaro and Zepbound is tirzepatide; no generic product exists.
- Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro.
Tirzepatide vs Zepbound vs Mounjaro: one molecule, two labels
Tirzepatide is the generic name, meaning the name of the molecule. Zepbound and Mounjaro are brand names, the names Lilly sells it under. Asking "tirzepatide vs Zepbound" is like asking "acetaminophen vs Tylenol": one is the ingredient, the other is the box. The reason there are two boxes is that the FDA approves a drug for a specific use, and Lilly ran separate trial programs for diabetes (SURPASS) and for weight (SURMOUNT).
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide. | Tirzepatide. |
| Maker | Eli Lilly. | Eli Lilly. |
| FDA approval | May 13, 2022 (NDA 215866). | November 8, 2023 (NDA 217806); sleep apnea added December 20, 2024. |
| Labeled use | Adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. | Chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity. |
| Strengths | 2.5, 5, 7.5, 10, 12.5, 15 mg. | 2.5, 5, 7.5, 10, 12.5, 15 mg. |
| Schedule | Once weekly; start 2.5 mg for 4 weeks, then 2.5 mg steps. | Same. |
| Trial program | SURPASS. | SURMOUNT. |
Source: Mounjaro and Zepbound prescribing information (DailyMed); FDA press releases of November 8, 2023 and December 20, 2024.
What is the generic name for Mounjaro?
Tirzepatide. When people search "Mounjaro generic name" or "generic Mounjaro," they usually mean one of two things. If they mean the ingredient, the answer is tirzepatide. If they mean a cheaper FDA-approved copy, there is none. Generic drugs are approved copies made after the brand's patents and exclusivity end, and no company has an approved generic tirzepatide. The same is true for "Zepbound generic": Zepbound has no generic.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Is tirzepatide the same as Zepbound? Is it the same as Mounjaro?
Yes to both, in the sense that tirzepatide is the drug inside each. Zepbound is tirzepatide. Mounjaro is tirzepatide. What differs is the labeled use, the trial program behind it, and often the insurance rules that follow from the label. Is there a difference between Zepbound and Mounjaro in the vial? The active ingredient and the strengths are the same. The prescribing information for each carries its own indication and its own trial results, which is why a prescriber writes one or the other depending on your diagnosis.
Is Zepbound for diabetes?
Zepbound is not labeled for diabetes. Mounjaro is. Does Zepbound help with diabetes anyway? Since it is the same molecule, tirzepatide's effect on blood sugar does not change with the name on the box, but the label is what matters for prescribing and coverage. In SURPASS-1, tirzepatide alone lowered A1c by 1.87 to 2.07 points over 40 weeks in adults with type 2 diabetes, and in SURMOUNT-2, adults with obesity and type 2 diabetes lost 12.8% (10 mg) and 14.7% (15 mg) of body weight over 72 weeks versus 3.2% on placebo.
| Trial | Population | Result |
|---|---|---|
| SURPASS-1 (40 weeks) | Type 2 diabetes, tirzepatide alone | A1c -1.87 (5 mg), -1.89 (10 mg), -2.07 (15 mg) points vs +0.04 placebo. |
| SURMOUNT-1 (72 weeks) | Obesity or overweight, no diabetes | Weight -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% placebo. |
| SURMOUNT-2 (72 weeks) | Obesity with type 2 diabetes | Weight -12.8% (10 mg), -14.7% (15 mg) vs -3.2% placebo. |
Source: SURPASS-1 (Rosenstock et al., Lancet 2021); SURMOUNT-1 (Jastreboff et al., NEJM 2022); SURMOUNT-2 (Garvey et al., Lancet 2023).
What does Zepbound do to your body? What is GIP?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Those are two gut hormones released after you eat. GLP-1 stands for glucagon-like peptide-1. GIP stands for glucose-dependent insulinotropic polypeptide. Tirzepatide copies both. The effects are lower appetite, slower stomach emptying, and more insulin release when blood sugar is high. So yes, Zepbound is a GLP-1 drug, and it is also a GIP drug. Semaglutide (Wegovy, Ozempic) acts on GLP-1 only, which is the main difference between the two families.
Is there a natural Zepbound or a Zepbound pill?
No. Products sold as "natural Zepbound" or "fit pills" do not contain tirzepatide. Tirzepatide is only approved as a once-weekly injection under the skin. No tablet form of tirzepatide is approved.
What this means for compounded tirzepatide
Compounded tirzepatide is a third thing, and it is not a generic. It is tirzepatide prepared per prescription by a state-licensed 503A compounding pharmacy. It is not FDA approved and it is not interchangeable with Zepbound or Mounjaro. It has no label of its own and no trial data of its own; the numbers above come from the branded products. A licensed provider decides whether a compounded medication is appropriate for you. FormBlends prices compounded tirzepatide at $149 for the first month, then $239 a month, or $214 with Subscribe & Save, at every dose; see pricing or begin the assessment.
Frequently Asked Questions
What is the brand name for tirzepatide?
Mounjaro and Zepbound. Both are Eli Lilly products containing tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity.
What is the generic name for Mounjaro?
Tirzepatide. There is no generic Mounjaro product on the market; tirzepatide is the ingredient name, not a generic you can buy.
Is tirzepatide the same as Zepbound?
Zepbound is tirzepatide. The drug inside Zepbound is tirzepatide at 2.5 to 15 mg once weekly. Zepbound is the brand name for the weight management and sleep apnea label.
Is Zepbound for diabetes?
Zepbound is not labeled for diabetes. Mounjaro, which contains the same drug, is labeled for type 2 diabetes. Your prescriber picks the product that matches your diagnosis.
Does Zepbound have a generic?
No. There is no FDA-approved generic tirzepatide. Compounded tirzepatide is sometimes called generic online, but it is not FDA approved and is not interchangeable with Zepbound.
Is there a difference between Zepbound and Mounjaro?
The active ingredient, strengths and schedule are the same. The labels differ: Mounjaro for type 2 diabetes, Zepbound for weight management and sleep apnea. That label difference drives which one is prescribed and how plans cover it.
Sources
- Mounjaro (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
- Zepbound (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
- FDA Approves New Medication for Chronic Weight Management, U.S. Food and Drug Administration, November 8, 2023.
- FDA Approves First Medication for Obstructive Sleep Apnea, U.S. Food and Drug Administration, December 20, 2024.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1), Rosenstock et al., The Lancet, 2021.
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), Jastreboff et al., New England Journal of Medicine, 2022.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2), Garvey et al., The Lancet, 2023.
- Compounding and the FDA: Questions and Answers, U.S. Food and Drug Administration.
Next steps
For the compounded side of the name question, read compounded tirzepatide vs Mounjaro. For the other drug family, see semaglutide vs tirzepatide and is Wegovy the same as tirzepatide. For prices, the tirzepatide cost guide. Browse the tirzepatide hub for every other tirzepatide question. Talk to a clinician about which product fits your diagnosis. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate for you.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →